Cellbyte, a Munich-based AI platform designed to shorten pharmaceutical drug launch timelines, has raised $2.75 million in seed funding. The round was led by Frontline Ventures, with participation from Y Combinator, Pace Ventures, Saras Capital, and Springboard Health Angels.
The funding will enable the company to expand internationally, triple its headcount, and automate more of the complex workflows involved in bringing new medicines to market.
Drug launches often face significant delays due to fragmented, outdated data infrastructure across the pharmaceutical industry. Market access teams spend substantial amounts of time producing documentation, preparing pricing strategies, and securing reimbursement approvals. These processes frequently require expensive third-party data or consulting support and can delay the delivery of critical therapies to patients for more than a year.
Cellbyte’s AI-native platform is designed to change that dynamic. The system analyzes millions of data points in real time across clinical, pricing, HTA, regulatory, and internal corporate sources. By providing fast, reliable insights, the platform supports the preparation of regulatory documents, optimizes launch sequences, and helps pharmaceutical companies devise more effective go-to-market strategies. Cellbyte positions itself as a modern alternative to legacy databases built before the rise of large language models, which offer only surface-level visibility into essential information.
The company says its technology reduces workflows that previously took many months down to minutes without compromising quality. This approach has quickly resonated with the market. Cellbyte has reached six figures in ARR within weeks of launching and has secured contracts with leading global pharmaceutical companies, including Bayer. The startup continues to expand across key international markets as demand increases.
Founded in 2024 by Daniel Moreira, Felix Steinbrenner, and Samuel Moreira, the company brings combined expertise in pharmaceutical consulting, AI, and machine learning, and startup operations. With fresh capital in hand, Cellbyte plans to scale its engineering organization and accelerate its trajectory toward becoming a core operating system for commercial pharmaceutical teams worldwide.
KEY QUOTES:
“The success of a drug’s entire lifecycle is decided in its launch sequence. Insights derived from gigabytes of accurate, up-to-date information are needed to make the best decisions for a launch. The traction Cellbyte has secured with some of the world’s biggest pharmaceutical companies since its launch shows the industry is ready to rethink drug launch workflows and adopt faster, higher quality and cost-effective processes.”
Felix Steinbrenner, Co-CEO and Co-Founder, Cellbyte
“Based on my years in Life Science Consulting, I’ve seen countless innovations transforming clinical development. Yet in Pricing and Market Access, decisions still too often rely on manual work and anecdotal evidence even though information is so abundant. Now, generative AI is changing that, and we’re proud to be driving this shift.”
Daniel Moreira, Co-CEO and Co-Founder, Cellbyte
“Cellbyte is tackling one of pharma’s biggest bottlenecks with an AI-driven strategy. Felix, Samuel and Daniel have set their sights globally from day one, and we’re proud to support them as they expand into the US, accelerating patient access to new treatments.”
William McQuillan, Partner, Frontline Ventures
